RegeneRx has designed each formulation to serve a number of target disease indications within a broad area of interest. Each indication is supported by patents and research data, much of which have been published in peer-reviewed scientific and medical journals. Although RegeneRx cannot pursue all of these indications, partners have an opportunity to optimize indications that are important to their own therapeutic area of focus.
(Tβ4 Eye Drop)
|Dry Eye Syndrome
Neurotrophic Keratopathy (orphan)
Recurrent Corneal Erosions
(Tβ4 Injectable Solution)
|Acute Myocardial Infarction (AMI)
Traumatic Brain Injury (TBI)
(Tβ4 dermal gel)
|Epidermolysis Bullosa (EB)
Pressure and Venous Stasis Ulcers
Scarring and Burns
**Stage 2 & 3, based on EU prevalence data and Clin Ophthalmol. 2014; 8: 571–579.